Although the focus of this work is on TACE-dependent EGFR activation as an alternative pathway of RFF, we have also been committed to study the participation of TGF-β on renal fibrosis after treatments with losartan, erlotinib or both losartan+erlotinib. This evidence concerns the gene EGFR and renal fibrosis.